Skip to content

Evaluating Dyspnea in Autoimmune Myasthenia Gravis "Why am I Short of Breath?"

Evaluating Dyspnea in Autoimmune Myasthenia Gravis "Why am I Short of Breath?"

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06866652
Acronym
MyaRESP
Enrollment
50
Registered
2025-03-10
Start date
2026-04-08
Completion date
2028-06-01
Last updated
2026-05-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyspnea, Myasthenia Gravis

Keywords

dyspnea, breathlessness, respiratory

Brief summary

Individuals with MG (IwMG) experience shortness of breath that may be activity-related, occur at rest and even happen during sleep. Dyspnea is a complex, multidimensional and multifactorial symptom involving sensory perception, cognition and emotion. Identifying the cause(s) of dyspnea in MG may assist in finding therapeutic strategies, reducing discomfort, improving QoL and potentially limiting respiratory deterioration and incidence of MG crisis.

Detailed description

MYaResp is a prospective observational, cross-sectional study to evaluate dyspnea in adults with autoimmune myasthenia gravis. Study aims include to: * Describe the characteristics of dyspnea in IwMG * Understand contributing factors and factors associated with dyspnea in IwMG including the relationship between patient-reported dyspnea, disease severity and functional limitations. * Determine the most effective tests to identify the causes and contributing factors of dyspnea

Interventions

None listed

Sponsors

Institut de Myologie, France
Lead SponsorOTHER
APHP
CollaboratorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥18 * Confirmed diagnosis of autoimmune MG * Shortness of breath in daily life: score 1 or 2 on the respiration item on the MG- activities of daily living score * Signed consent form * Affiliated to or beneficiary of a social security scheme

Exclusion criteria

* Known Pregnancy * Known respiratory disorder (other than MG) * Recent (within past 4 weeks) respiratory infection * Current MG crisis or exacerbation (necessitating increase in MG medication \&/or hospital admission) * No dyspnea - score 0 or 3 on the respiration item on the MG- activities of daily living score * Severe cognitive impairment/guardianship

Design outcomes

Primary

MeasureTime frameDescription
Dyspnea questionnairesbaselineDyspnea-12

Secondary

MeasureTime frameDescription
cardiopulmonary exercise testbaselinecycle ergometer
Polysomnographybaselineevaluation of sleep disordered breathing
Functional measuresbaseline6 minute walk test
Quality of life questionnairesbaselineRevised version of the myasthenia gravis quality of life questionnaire (Burns, French validation Birnbaum)
Anxiety and depressionbaselineHospital Anxiety and Depression Scale

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 9, 2026